Você procurou por: myelotoksicitet (Dinamarquês - Inglês)

der er i sjældne tilfælde blevet indberettet rhabdomyolyse - sædvanligvis associeret med myelotoksicitet, alvorlige
rhabdomyolysis has been uncommonly reported, usually in association with myelotoxicity, severe liver function test abnormalities and/ or renal failure.

risikoen for alvorlig myelotoksicitet og langvarig immunsuppression er øget hos patienter med sygdomsrelateret knoglemarvsinfiltration eller en tidligere myelosuppressiv behandling.
the risk of severe myelotoxicity and long-lasting immunosuppression is increased in patients with a disease-related bone marrow infiltration or a previous myelosuppressive treatment.

hvis myelotoksicitet forsinker behandlingen mere end 35 dage efter den første dosis af den foregående cyklus, bør det overvejes helt at ophøre med behandlingen.
if myelotoxicity delays treatment to greater than 35 days after the first dose of the previous cycle, then consideration should be given to stopping treatment.

mabthera er blevet anvendt til 21 patienter, som havde fået foretaget autolog knoglemarvstransplantation, og til andre risikogrupper med formodet nedsat knoglemarvsfunktion uden at fremkalde myelotoksicitet.
mabthera has been used in 21 patients who underwent autologous bone marrow transplantation and other risk groups with a presumable reduced bone marrow function without inducing myelotoxicity.

mabthera er blevet anvendt til 21 patienter, som havde fået foretaget autolog knoglemarvstransplantation, og til andre risiko grupper med formodet nedsat knoglemarvsfunktion uden at fremkalde myelotoksicitet.
mabthera has been used in 21 patients who underwent autologous bone marrow transplantation and other risk groups with a presumable reduced bone marrow function without inducing myelotoxicity.

ved studier med gentagne doser hos mus, rotter og hunde var de vigtigste fund myelotoksicitet, nefrotoksicitet (bortset fra hunde) og testikelbeskadigelse.
in repeated-dose studies in mice, rats, and dogs, the main findings were myelotoxicity, nephrotoxicity (except dogs), and testicular damage.

der er i sjældne tilfælde blevet indberettet rabdomyolyse - sædvanligvis associeret med myelotoksicitet, alvorlige abnormiteter i leverfunktionstests og/eller nyre- eller multiorgansvigt.
rhabdomyolysis has been uncommonly reported, usually in association with myelotoxicity, severe liver function test abnormalities and/or renal or multiorgan failure.

denne myelotoksicitet var reversibel inden for 4 til 6 uger efter ophør af hcv-antiviral-behandling sammen med azathioprin og opstod ikke igen ved genoptagelse af behandlingerne hver for sig (se pkt.
this myelotoxicity was reversible within 4 to 6 weeks upon withdrawal of hcv antiviral therapy and concomitant azathioprine and did not recur upon reintroduction of either treatment alone (see section 4.5).

hvis den maksimalt tolererede dosis ikke nås, opstår der normalt forbigående myelotoksicitet hos mindre end 10% af patienterne, mens mere end 50% kan opleve reversibel knoglemarvshæmning under den maksimalt tolererede dosis.
when the maximum tolerated dose is not reached transient myelotoxicity usually occurs in less than 10% of patients, while under the maximum tolerated dose more than 50% can experience reversible bone marrow suppression.

denne myelotoksicitet var reversibel inden for 4 til 6 uger efter ophør af hcv-antiviral-behandling sammen med azathioprin og opstod ikke igen ved genoptagelse af behandlingerne hver for sig (se afsnit 4.5).
this myelotoxicity was reversible within 4 to 6 weeks upon withdrawal of hcv antiviral therapy and concomitant azathioprine and did not recur upon reintroduction of either treatment alone (see section 4.5).